Table 3.
Bevacizumab
| Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 1 | Patient 2 | Patient 10 | Patient 11 | Patient 12 | |
|---|---|---|---|---|---|---|---|---|---|
| Age at FD | 37 | 61 | 26 | 64 | 74 | 42 | 58 | 49 | 52 |
| MM/YY FD | 11/17 | 03/16 | 04/15 | 11/17 | 11/17 | 07/12 | 03/16 | 01/16 | 01/18 |
| History of disease/time to recurrence (months) | 1. surgery, RCTX/5; 2. loc rec -> surgery/2; 3. loc rec -> surgery/3; 4. loc rec -> CTX (carboplatin/paclitaxel/bevacizumab)/4; 5. loc and dist rec-> ctx with mitomycin/capecitabine/3; 6. loc PD: pembrolizumab/4; 7. loc and dist PD: best supp care |
1. surgery, RT/11; 2. dist rec -> CTX (cisplatin/topotecan)/9; 3. loc PD -> CTX (paclitaxel/bevacizumab)/13; 4. dist rec -> pembrolizumab/3; 5. dist PD -> best supp care |
1. surgery, RTX/10; 2. loc rec -> surgery R0/3; 3. dist rec -> CTX (carboplatin/paclitaxel/bevacizumab)/6; DVT: end of bevacizumab, start pembrolizumab/3; 4. dist. rec -> CTX vinorelbine |
1. surgery/11; 2. loc rec -> surgery (R1) -> RT/10; 3. loc and dist rec -> CTX (carboplatin/paclitaxel/bevacizumab) |
1. surgery, adj. RT/6; 2. loc rec -> surgery R0/2; 3. loc rec -> surgery, R0, adj RCTX; 4. loc rec under ongoing RT -> CTX carboplatin/paclitaxel/bevacizumab/4; 5. dist rec -> erlotinib |
1. surgery, adj. RCTX/8; 2. local and dist rec/4 (parallel) -> surgery, RCTX; 3. loc PD -> erlotinib/3; 4. Loc dist. PD -> CTX (carboplatin/paclitaxel/bevacizumab)/4 |
1. surgery/10; 2. loc rec -> RCTX/6; 3. loc rec -> surgery (R0) + CTX (cisplatin, paclitaxel)/10; 4. loc rec -> surgery (R1) -> RCTX/7; 5. loc PD -> CTX (carboplatin/paclitaxel/bevacizumab)/12; 6. loc PD -> CTX (paclitaxel mono) |
1. surgery, adj. local ablative RT/8; 2. dist rec -> RT/7; 3. dist rec -> stereotactic irradiation/9; 4. dist PD -> CTX cisplatin/paclitaxel/bevacizumab |
1. surgery -> RCTX/7; 2. loc rec -> CTX (carboplatin/paclitaxel/bevacizumab)/6 carboplatin/paclitaxel intolerance, bevacizumab maintenance; 3. loc rec -> olaparib (known BRCA mutation) |
| Disease at indication (tumor load) | Local PD (Vulva) | Local PD (Vulva) | Distant metastasis (bone) | Local and distant PD (right groin, liver) | Local PD (vulva) | Local and distant PD (right groin, skin) | Local PD (right groin) | Distant metastasis (lung, liver) | Local PD (left groin) |
| HPV status | Unknown | Unknown | Unknown | Negative (p16−) | Unknown | Unknown | Unknown | Unknown | Unknown |
| Best response | PD | CR | PD | SD | PR | PD | CR | SD | SD |
| Side effects | Grade 2 CTCAE: high blood pressure | Grade 2 CTCAE: pericardial effusion | Grade 3 CTCAE: DVT | Grade 2 CTCAE: diarrhea, lymphedema, high blood pressure | Grade 3 CTCAE: high blood pressure | None | Grade 3 CTCAE: arterial bleeding right groin 2 months after end of bevacizumab | None | None |
| Dose reduction | No | No | Yes, end of bevacizumab (DVT) | No | Yes, end of bevacizumab (high blood pressure resistant to therapy) | No | No | No | No |
| Time to progression | 4 months | 13 months | 6 months | Ongoing treatment | 4 months | 4 months | 12 months | Ongoing treatment | 6 months |
| Time to death from FD | Unknown | Unknown | 40 months | Unknown | Unknown | 36 months | 48 | NA | Unknown |
| Cause of death | Unknown | Unknown | Tumor progression | Unknown | Unknown | Tumor progression | Tumor progression | NA | Unknown |
adj., adjuvant; CTCAE, Common Terminology Criteria for Adverse Events; HPV, human papilloma virus; loc, local; dist, distant; rec, recurrence; MM/YY FD, month/year of first diagnosis; PD, progressive disease; RD, recurrent disease; SD, stable disease; CR, complete response; PR, partial response; FD, first diagnosis; CTX, chemotherapy; RT, radiotherapy; CRTX, chemoradiation; R0, tumor-free margins; R1, microscopic tumor residual; DVT, deep vein thrombosis.